Jade Biosciences (JBIO) Share-based Compensation (2020 - 2026)
Jade Biosciences posted quarterly Share-based Compensation of $7.4 million for Q1 2026, up 205.61% year-on-year from $2.4 million in Q1 2025, and down 21.19% on a QoQ basis from $9.4 million in Q4 2025.
Jade Biosciences (JBIO) has 7 years of Share-based Compensation data on file, last reported at $7.4 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 205.61% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (up 230.09% YoY), and the FY2025 full-year result was $20.0 million, up 76.9% from the prior year.
- Share-based Compensation for Q1 2026 stood at $7.4 million, down from $9.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $9.4 million in Q4 2025 and bottomed at $27000.0 in Q3 2024.
- The 5-year median for Share-based Compensation is $3.0 million (2023), against an average of $3.2 million.
- The widest annual swing landed in 2024, when Share-based Compensation plunged 99.17%; it then jumped 15807.41% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.7 million in 2022, then jumped by 88.03% to $3.3 million in 2023, then tumbled by 61.37% to $1.3 million in 2024, then surged by 648.09% to $9.4 million in 2025, then declined by 21.19% to $7.4 million in 2026.
- The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $9.4 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | 7.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.41 Mn |
| Mar 31, 2026 | 7.41 Mn |
| Dec 31, 2025 | 9.40 Mn |
| Dec 31, 2025 | 9.40 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 3.90 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 3.87 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Mar 31, 2024 | 4.20 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Dec 31, 2023 | 3.25 Mn |
| Sep 30, 2023 | 3.24 Mn |
| Sep 30, 2023 | 3.24 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Jun 30, 2023 | 3.03 Mn |
| Mar 31, 2023 | 2.38 Mn |
| Mar 31, 2023 | 2.38 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 854,000.00 |
| Dec 31, 2021 | 854,000.00 |
| Sep 30, 2021 | 845,000.00 |
| Sep 30, 2021 | 845,000.00 |
| Jun 30, 2021 | 321,000.00 |
| Jun 30, 2021 | 321,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Dec 31, 2020 | 24,000.00 |
| Dec 31, 2020 | 24,000.00 |
| Sep 30, 2020 | 21,000.00 |
| Sep 30, 2020 | 21,000.00 |
| Jun 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 6,000.00 |